Controversial areas in chronic hepatitis B (CHB) are those where there is uncertainty, or differences of opinion in management, or where evidence may be insufficient. Areas of controversy include whether patients with high viral load but normal liver function tests should be treated to prevent hepatocellular carcinoma (HCC) or liver disease progression to cirrhosis. Another area is whether quantitative hepatitis B surface antigen (qHBsAg) can be used to better characterize phases of CHB and prognosticate. Finally, the utility of qHBsAg in the management of patients on antiviral therapy such as interferon and nucleoside analogues could improve management practices.
All Keywords
【저자키워드】 Treatment, interferon, Nucleoside analogues, HBsAg, HBV DNA, qHBsAg, Phase change, Stopping therapy,
【저자키워드】 Treatment, interferon, Nucleoside analogues, HBsAg, HBV DNA, qHBsAg, Phase change, Stopping therapy,